Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes

Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes.
A further drug, the in front in its class, gives added blood sugar command to common people with type 2 diabetes who are already taking the glucose-lowering medication metformin. The reborn agent, dapagliflozin, which also helped patients be deprived of weight, is novel in that it does not work entirely on the body's insulin mechanisms, according to a study appearing in the June 26 come of The Lancet and slated for presentation at the annual convention of the American Diabetes Association (ADA) in Orlando worldplusmed.net. "It will unquestionably be used as an add-on therapy," said study standard author Clifford Bailey, a chemical pathologist and professor of clinical subject at Aston University in Birmingham, UK "If you don't altogether get to target with the first therapy tried, this overtures to would offer you an opportunity hopefully to maintain improved control".

Bailey, who could not presage if or when the drug might get final approval from drug regulatory authorities, also apiculate out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any status in the disease. "It's a good add-on," agreed Dr Stanley Mirsky, fellow-worker clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City. "Is it a inquire drug? No. It may frivolity a little role".

The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin insides by stimulating the kidneys to rule out more glucose from the body via urine. In this study of 534 mature patients with type 2 diabetes who were already taking metformin, the highest dosage of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent shrink in HbA1c levels.

HbA1c is a measure of blood sugar exercise power over time. Participants taking 5 mg of the treatment saw a 0,70 percent decrease in HbA1c levels, while those taking 2.5 mg had a 0,67 percent decrease. In the placebo group, the lowering in HbA1c was 0,3 percent, the mug up found.